Marginal Zone B-cell Lymphoma – Drugs In Development, 2023

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry


Global Markets Direct’s, ‘Marginal Zone B-cell Lymphoma – Drugs In Development, 2023’, provides an overview of the Marginal Zone B-cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Marginal Zone B-cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marginal Zone B-cell Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


*Certain sections in the report may be removed or altered based on the availability and relevance of data.

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase

* Global Markets Direct, is a research brand owned and operated by GlobalData.


  • The report provides a snapshot of the global therapeutic landscape of Marginal Zone B-cell Lymphoma

  • The report reviews pipeline therapeutics for Marginal Zone B-cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Marginal Zone B-cell Lymphoma therapeutics and enlists all their major and minor projects
  • The report assesses Marginal Zone B-cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Marginal Zone B-cell Lymphoma

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Marginal Zone B-cell Lymphoma

  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Marginal Zone B-cell Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Key Players

AbbVie Inc
Abclon Inc
Accutar Biotechnology Inc
Achelois BioPharma Inc
Adicet Bio Inc
Advenchen Laboratories LLC
Allarity Therapeutics Inc
Allogene Therapeutics Inc
ALX Oncology Holdings Inc
Amgen Inc
Antengene Corp Ltd
AstraZeneca Plc
Aurigene Oncology Ltd
Autolus Therapeutics Plc
BeiGene Ltd
Beijing Luzhu Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Bellicum Pharmaceuticals Inc
Bio-Path Holdings Inc
BioInvent International AB
BioNova Pharmaceuticals Ltd
Boryung Pharmaceutical Co Ltd
Boston Immune Technologies and Therapeutics Inc
Bristol-Myers Squibb Co
Byondis BV
California Institute for Biomedical Research
CARGO Therapeutics Inc
Caribou Biosciences Inc
Carna Biosciences Inc
CASI Pharmaceuticals Inc
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellectis SA
Century Therapeutics Inc
Chengdu Hyperway Pharmaceutical Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
CHO Pharma Inc
CoImmune Inc
CSPC Pharmaceutical Group Ltd
Cullinan Oncology Inc
Curis Inc
Curon Biopharmaceutical Ltd
Daiichi Sankyo Co Ltd
Debiopharm International SA
Dizal Pharmaceutical Co Ltd
Duet Therapeutics Inc
Eli Lilly and Co
Enterome Bioscience SA
Evopoint Bioscience Co Ltd
F. Hoffmann-La Roche Ltd
Fosun Pharma Kite Biotechnology Co Ltd
Galapagos NV
Gamida Cell Ltd
GC Cell Corp
Genentech USA Inc
General Hospital of the People's Liberation Army
Genmab AS
Gilead Sciences Inc
Gracell Biotechnologies Inc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangdong Second Provincial General Hospital
Guangzhou BeBetter Medicine Technology Co Ltd
Haisco Pharmaceutical Group Co Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
Hebei Senlang Biotechnology Co Ltd
Hibercell Inc
Hualan Biological Engineering Inc
Huazhong University of Science & Technology
Hutchison MediPharma Ltd
IGM Biosciences Inc
ImmuneOncia Therapeutics Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunoAct Pvt Ltd
Incyte Corp
Innate Pharma SA
InnoCare Pharma Ltd
Innovent Biologics Inc
Institute of Biomedical Research of Salamanca
Ipsen SA
ITabMed Co Ltd
Janssen Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JW Cayman Therapeutics Co Ltd
Karyopharm Therapeutics Inc
KeyMed Biosciences Inc
Lanzhou Institute of Biological Products Co Ltd
Les Laboratoires Servier SAS
Light Chain Bioscience
Loxo Oncology Inc
Marino Biotechnology Co Ltd
Massachusetts General Hospital
Mayo Clinic
Medical College of Wisconsin
MEI Pharma Inc
Merck & Co Inc
Miltenyi Biomedicine GmbH
MiNK Therapeutics Inc
MorphoSys AG
Mustang Bio Inc
Nagoya University Hospital
Nanjing Sanhome Pharmaceutical Co Ltd
National Taiwan University Hospital
Newave Pharmaceutical Inc
Nkarta Inc
Novartis AG
Nurix Therapeutics Inc
Oncternal Therapeutics
PeproMene Bio Inc
Prelude Therapeutics Inc
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Regeneron Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Salarius Pharmaceuticals Inc
Sana Biotechnology Inc
Secura Bio Inc
SELLAS Life Sciences Group Inc
Shandong New Time Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Biosciences Co Ltd
Shanghai Longyao Biotechnology Co Ltd
Shengke Pharmaceuticals (Jiangsu) Ltd
SIRPant Immunotherapeutics Inc
Sorrento Therapeutics Inc
Spexis AG
Stemline Therapeutics Inc
Step Pharma
Sunnycell Therapeutics Ltd
Suzhou Fundamenta Therapeutics Co Ltd
Swedish Orphan Biovitrum AB
SymBio Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
TG Therapeutics Inc
TransThera Sciences (Nanjing) Inc
Triphase Accelerator Corp
UNC Lineberger Comprehensive Cancer Center
University of Colorado Denver
University of Texas MD Anderson Cancer Center
UTC Therapeutics Inc
Waterstone Hanxbio Pty Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Xuzhou Medical College
Xuzhou Medical University
Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd
Zai Lab Ltd
Zentalis Pharmaceuticals Inc
Zhejiang Borui Biopharmaceutical Co Ltd
Zhejiang DTRM Biopharma LLC
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Longchuan Biomedical Technology Co Ltd
Zhejiang Teruisi Pharmaceutical Co Ltd
Zhejiang University
Zhejiang University School of Medicine Hospital 1
Zibo Baiji Changsheng Pharmaceutical Co Ltd

Frequently asked questions

Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Marginal Zone B-cell Lymphoma – Drugs In Development, 2023 in real time.

  • Access a live Marginal Zone B-cell Lymphoma – Drugs In Development, 2023 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.